Preferred Label : Burosumab;
NCIt synonyms : Anti-FGF23 IgG1 Monoclonal Antibody KRN23; Burosumab-TWZA;
NCIt definition : An orally bioavailable recombinant human immunoglobulin G1 monoclonal antibody directed
against human fibroblast growth factor 23 (FGF23), that can be used to increase serum
phosphate levels. Upon subcutaneous administration, burosumab binds to and inhibits
FGF23, thereby interfering with FGF23 signaling. This increases tubular phosphate
reabsorption, decreases excretion of phosphate, and increases serum phosphate levels,
resulting in enhanced bone mineralization. FGF23, a member of the fibroblast growth
factor (FGF) family produced by osteocytes, plays a key role in hypophosphatemic rickets/osteomalacia,
such as X-linked hypophosphatemia (XLH) and tumor-induced rickets/osteomalacia. Increased
FGF23 levels lead to decreased expression of the sodium-phosphate co-transporters
in the proximal tubules, reduced renal phosphate reabsorption, increased excretion
by the kidneys, and low serum phosphate concentration.;
UNII : G9WJT6RD29;
CAS number : 1610833-03-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1610833-03-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Drug name : Crysvita;
Molecule name : UX023; KRN23;
Origin ID : C119744;
UMLS CUI : C4301607;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
